Secondary acute lymphocytic leukemias (ALL) are uncommon events in the pediatric patient population. There are few detailed reports on the laboratory characteristics and clinical course of patients with secondary lymphocytic leukemia. Historically, these patients have had a poor outcome. We report two patients treated at one institution who developed treatment-related secondary ALL. Both patients underwent hematopoietic stem cell transplantation, one with a compatible unrelated donor cord blood unit and one with an HLA-matched sibling donor bone marrow. One of the two patients survives disease-free 3 years after transplantation.
Secondary leukemias are uncommon but known risks in children who have survived treatment with radiation and chemotherapy. Risk factors associated with secondary leukemias include exposure to topoisomerase II inhibitors, alkylating agents and prior radiation therapy. The majority of secondary leukemias reported are acute myeloid leukemias (AML). [1] [2] [3] Secondary AML has been reported to have a cumulative risk of 5.9% at 4 years and 3.8% risk at 6 years in two separate studies of children with acute lymphocytic leukemia who were treated with etoposide (VP16). 4, 5 In contrast to secondary AML, secondary ALL is an uncommon occurrence. [6] [7] [8] [9] [10] The treatment of secondary ALL with unrelated donor marrow transplantation has been reported, with data on one child with a disease-free survival of 14+ months. 11 However, the medical literature contains few detailed reports on the characteristics of this disease and the treatment of children with secondary ALL. We report two children with secondary ALL who underwent hematopoietic stem cell transplant, one with an unrelated donor cord blood and one with an HLA-matched sibling donor bone marrow as treatment of their disease.
Case 1
A 3-year-old Caucasian male was diagnosed with disseminated Burkitts's lymphoma in October 1992. He presented with history of fevers, night sweats and a swollen face. Initial examination showed bilateral cervical adenopathy, enlarged kidneys, leukemic infiltration of the pancreas, and 30% lymphoblasts in the bone marrow. Bone marrow aspiration demonstrated 92% blasts. There was no CNS involvement. The lymphoblasts were negative for myeloperoxidase, PAS and alpha naphthyl butyrate esterase. The morphology of the lymphoblasts was FAB-L2. Flow cytometric analysis of the bone marrow showed expression of CD45 (dim)/TdT/surface CD3/cytoplasmic CD3/CD1A/CD5/CD2/CD38/CD7 positive and HLA DR negative. Cytogenetic analysis of the marrow blasts demonstrated an abnormal karyotype with two clones; 46,XY,t(4;11)(q21;p15), and del(5)(q31)/45,idem,del(6) (q21),-21. There was no evidence of MLL gene arrangement by FISH analysis. The morphology, flow cytometric analysis and cytogenetics were diagnostic for acute lym-phocytic leukemia with a T cell immunophenotype. The patient was treated with a standard four-drug induction regimen consisting of daunomycin, prednisone, vincristine and Peg l-asparaginase. The induction was well tolerated with complete morphologic remission achieved in June 1998. The patient did not have an HLA-compatible family member. A donor search of the New York Blood Center identified a compatible unrelated donor cord blood unit that was mismatched at a single HLA DR B1 locus. He received a conditioning regimen of total body irradiation (1440 cGy in 12 fractions) with a 400 cGy boost to the testicles. This was followed by cyclophosphamide (60 mg/kg for 2 days) and antithymocyte globulin (30 mg/kg for 7 days). 12 Graftversus-host disease prophylaxis consisted of cyclosporine and short-course methotrexate. He was infused with unrelated donor cord blood that contained 0.95 × + cells/kg. He showed evidence of engraftment of host origin 6 days later, with an ANC greater than 500 cells/mm 3 9 days after autologous reinfusion. The transplant course was complicated by pericardial effusion and tamponade, capillary leak syndrome, and respiratory failure. He was discharged from the hospital on day +66 from unrelated cord blood transplant and day +28 from autologous peripheral blood stem cell infusion. He remained in remission until 11 months post transplantation, when he suffered a marrow relapse. Morphologic examination of the bone marrow aspirate was consistent with his original secondary ALL. He was subsequently treated on the Pediatric Oncology Group Protocol 9673 with Compound 506U78 for two cycles followed by treatment according to a St Jude's continuation protocol. 13 He entered a brief period of remission after compound 506U78, but subsequently failed further salvage chemotherapy. He died 22 months after hematopoietic stem cell transplantation of progressive leukemia.
Case 2
A 5.-year-old Caucasian female was diagnosed with stage IV Wilm's tumor in April 1995. She presented with a rightsided abdominal mass, pulmonary and liver metastases as well as peritoneal seeding. She was initially treated according to National Wilm's Tumor Study (NWTS) IV protocol, regimen DD4a, receiving adriamycin, actinomycin D and vincristine, 1050 cGY abdominal radiation, and 1200 cGY thoracic radiation. She completed therapy with few complications. Thirty-one months after her initial diagnosis she presented with abdominal pain. A CT scan of the abdomen revealed splenomegaly without hepatomegaly. Laboratory tests showed a WBC of 195 000 cells/mm 3 with 95% peripheral blasts, a hemoglobin of 2.5 gm/dl and a platelet count of 21 000 cells/mm 3 . Bone marrow biopsy revealed 95% blasts. There was no CNS involvement. The lymphoblasts were morphologically FAB-L2. They were negative for myeloperoxidase, positive for PAS with focal dot positivity for alpha naphthyl butyrate esterase. Flow cytometric analysis of the bone marrow demonstrated blasts that were positive for CD34/TdT/DR/CD15/CD19 cytoplasmic IgM, and negative for CD10, CD13 and CD33. Cytogenetic analysis of the marrow blasts demonstrated a karyotype of 46,XX,t(4;11)(q21;q23). There was evidence of MLL gene arrangement by FISH analysis. The morphology and cytochemical and immunophenotypic findings were consistent with acute lymphocytic leukemia, pre-B cell immunophenotype. She was treated with a four-drug induction chemotherapy regimen including daunorubicin, prednisone, vincristine and l-asparaginase. She had a morphologic and karyotypic remission by day +30 of induction chemotherapy. After induction therapy she received interim maintenance therapy similar to the CCG protocol 1961 which consisted of daily 6-mercaptopurine, weekly methotrexate and monthly vincristine and prednisone. She underwent an HLA-matched sibling donor bone marrow transplant after a conditioning regimen of busulfan (1 mg/kg p.o. every 6 h for 4 days) and melphalan (60 mg/m 2 i.v. over 3 days). Graft-versus-host disease prophylaxis consisted of cyclosporine plus short-course methotrexate. She was infused with 3.6 × 10 8 mononuclear cells/kg. Her transplant was complicated by grade 2 graft-versus-host disease of the skin that was successfully treated with a course of steroids. She had confirmation of donor engraftment on day +106. Transplant-related complications included hemorrhagic cystitis, pneumonitis and anorexia. She survives disease free 3 years post transplantation.
Discussion
Treatment-related acute lymphoblastic leukemia is a rare complication of childhood cancer therapy. This disease has been previously estimated to occur in only 5-10% of the cases of secondary leukemias that arise in children and adults. A review of the literature reveals that childhood secondary ALL is an uncommon event, with little data on the clinical, laboratory and karyotypic characteristics of this disease. [6] [7] [8] [9] [10] The patients in this report had the characteristic risk factors for the development of secondary leukemias. They were both previously exposed to topoisomerase II inhibitors, and one patient also had radiation therapy. Prior therapy with topoisomerase II inhibitors has been shown have a cumulative 6 year risk of secondary leukemia in the range of 0.7 to 3.3%. 2, 3 Secondary leukemias associated with prior topoisomerase II inhibitor therapy generally have a different clinical course compared to alkylating-agent containing chemotherapy. Leukemias secondary to topoisomerase II inhibitors usually include a relatively short latency period, are often associated with translocations involving the MLL gene and are most commonly AML of the M4 or M5 FAB subtypes. The MLL gene located at chromosome band 11q23 partners with multiple breakpoints of several chromosomes in both primary and secondary leukemia. The karyotype of patient UPN 489 involved a t(4;11)(q21;q23). This translocation, which fuses MLL to AF4, accounts for about half of all MLL translocations and is commonly observed in de novo infant ALL.
14 This patient also lacked CD10 and had co-expression of the myeloid-associated antigen CD15. This aberrant phenotype pattern is usually seen in patients with B lineage ALL with the t(4;11)(q21;23). 15 There is only a single reported survivor of secondary ALL. 11 Thirteen of the 21 previously reported patients subsequently died from the therapy or relapse, with no survival data in the remainder of patients. Of note, the only reported survivor was also treated with hematopoietic stem cell transplantation.
11
In this report, both patients with secondary ALL underwent hematopoietic stem cell transplantation, one with an HLA matched sibling donor and one with an unrelated donor cord blood. The patient with a matched sibling donor is currently disease-free more than 2 years from transplantation. The patient who received an unrelated donor cord blood did not engraft, and was subsequently reinfused with autologous stem cells. This patient remained disease-free for almost 1 year after the autologous reinfusion, and survived almost 2 years after his transplant. Our experience is consistent with that reported by Leahey et al, 11 which suggests that hematopoietic stem cell transplantation is potentially curative for children with this rare disease.
